Overview

Phase 1A Safety Trial of Inhaled PK10571 (GB002)

Status:
Completed

Trial end date:
2018-12-03

Target enrollment:

Participant gender:

Summary

This is a phase 1A randomized double blind placebo controlled single ascending dose and multiple ascending dose trial of inhaled PK10571 (GB002) in healthy adult subjects.

Phase:

Phase 1

Details

Lead Sponsor:

GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Gossamer Bio Inc.

Collaborators:

Pulmokine Inc.
Worldwide Clinical Trials